


Substitute for Form 1449 A & B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/517,137
		Confirmation Number	6831
		Filing Date	December 07, 2004
		First Named Inventor	Rian VAN MEETEREN
		Art Unit	Unknown 1614
Examiner Name	LESLIE A. ROYDS		
Sheet	1	of	1
		Attorney Docket Number	Q84960

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
LAR		EP	801 067	A1	10-15-1997	Yamanouchi Pharmaceutical Co., Ltd.	
LAR		WO	96/38143	A1	12-05-1996	Synaptic Pharmaceutical Corp.	
LAR		WO	99/57131	A1	11-11-1999	Duke University	
LAR		EP	34 432	A2	08-26-1981	Yamanouchi Pharmaceutical Co. Ltd.	
LAR		EP	1 088 551	A1	04-04-2001	Yamanouchi Pharmaceutical Co. Ltd.	
LAR		EP	1 203 582	A1	05-08-2002	Yamanouchi Pharmaceutical Co. Ltd.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
LAR		SELLERS, Donna J. et al, "Potential therapeutic targets for the treatment of the overactive bladder", World Journal of Urology, vol. 19, no. 5, p307-311, 2001	
LAR		SCARPA, R.M. "Lower Urinary tract symptoms: what are implications for the patients?" European Urology, vol. 40, suppl. 4, p12-20, 2001	
LAR		Current Therapy, vol. 19, no. 12, p8-11, 2001, with English translation	
LAR		Urology, vol. 55, suppl. 5a, p1-2, 2000	
LAR		Medicines and Drug Journal, vol. 38, S-1, p283-288, 2002, with English translation	
LAR		BJU International, vol. 85, suppl. 2, p6-11, 2000	
LAR		Shinyaku-to-Rinsho, vol. 44, no. 8, p61-64, 1995, with English translation	
LAR		BJU International, vol. 85, Suppl. 2, p25-30, 2000	
LAR		Neurology and Urodynamics, vol. 17, No. 1, p31-36, 1998	
LAR		European Urology, vol. 36, Suppl. 1, p89-95, 1999	
LAR		European Urology Supplements, 2, No. 1, p171, 674, 2003	
LAR		Japan Pharmaceutical Reference, Products and Administration in Japan, The Fifth Edition (1999), p1263-1265	
LAR		AHFS Drug Information 2000, p3712-3713	

Examiner Signature		Date Considered	07 DECEMBER 2005
--------------------	---	-----------------	------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.